Endotelix is a privately held Swiss biotech start-up company and a spin-off from the University of Geneva. Endotelix is dedicated to providing fast, sensitive and reliable solutions for Antiphospholipid Syndrome, including diagnostic tests and therapies
Location: Switzerland, Geneva, Plan-les-Ouates
Employees: 1-10
Founded date: 2019
Investors 2
| Date | Name | Website |
| - | Venture Ki... | venturekic... |
| 21.10.2022 | VentureLab | venturelab... |
Mentions in press and media 7
| Date | Title | Description | Source |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | startuptic... | |
| 16.03.2023 | FIF Funding for three new Geneva projects | The FIF is the instrument for fostering innovation and scale up of promising companies from the Cant... | startuptic... |
| 28.01.2020 | Diagnostic and cleantech start-ups get the first CHF150,000 ... | startuptic... | |
| 28.01.2020 | Diagnostic and cleantech start-ups get the first CHF150,000 ... | For 2020, the philanthropic initiative is allocating CHF5 million to 80 new innovative startup proje... | startuptic... |
| 03.06.2019 | Die Gewinner der Swissbiolabs Challenge stehen fest | startuptic... | |
| 27.12.2018 | Ten early stage deep-tech startups compete for Imagine IF! a... | startuptic... | |
| 16.10.2018 | Scailyte wins Start JLM competition | startuptic... |